source
- Roche’s dual GLP-1/GIP drug enicepatide lowers HbA1c in phase 2 trial, sparking best-in-disease hopesRoche reported that its dual GLP-1/GIP receptor agonist, enicepatide, met the primary goals of a phase 2 study in patients with type 2 diabetes. The top 24‑mg weekly dose reduced HbA1c by 2.65% ove…
- Amgen reports positive Phase 3 results for Sjögren's drug; Novartis announces $900M radioligand partnershipAmgen said its CD40 ligand antagonist dazodalibep met the primary endpoint in a Phase 3 trial for Sjögren's syndrome, marking a notable achievement for the company. Novartis disclosed a $900 milli…Endpoints · 29d agoPositive readoutPositive